Expression of Pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas
Expression of Pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas
复制标题
Pax8 的表达是区分卵巢癌和乳腺癌的有用标记物
DOI：
10.1097/pas.0b013e31816d71ad
复制
发表时间：
2008-10-01
影响因子：
5.6
通讯作者：
Soslow, Robert A.
中科院分区：
文献类型：
--
作者：
Nonaka, Daisuke;Chiriboga, Luis;Soslow, Robert A.
卵巢是转移的常见部位，而乳房是最常见的来源之一。转移性乳腺癌可以模仿原发性卵巢癌。 Pax8 是甲状腺、肾脏和苗勒管系统器官发生的关键转录因子，它还调节肾母细胞瘤抑制基因 (WT1) 的表达。组织芯片对124例卵巢癌（浆液性乳头状癌84例，子宫内膜样癌18例，粘液性癌12例，透明细胞癌10例）和浸润性乳腺癌243例（导管癌178例，小叶状癌65例）进行免疫染色，观察Pax8和WT1的差异表达情况。 Pax8 反应在 124 例卵巢癌中的 108 例 (87.1%) 中发现，通常呈弥漫性染色，其中包括 84 例浆液性乳头状癌中的 81 例 (96.4%)。 18 例子宫内膜样癌中的 16 例 (88.9%)、10 例透明细胞癌中的 10 例 (100%) 和 12 例粘液癌中的 1 例 (8.3%)，而 124 例卵巢癌中的 78 例 (62.9%) 中观察到 WT1 表达，其中包括 84 例浆液性乳头状癌中的 73 例 (86.9%) 和 18 例中的 5 例子宫内膜样癌（27.8%），在所有 10 例透明细胞癌和 12 例粘液性癌中均无表达。所有乳腺癌均 Pax8 完全阴性，但 243 例中有 5 例 (2.1%) 可见 WT1 表达。 Pax8 是鉴别诊断卵巢癌和乳腺癌的有用标志物，对于所有类型的非粘液性卵巢癌的诊断，它似乎优于 WTI，尤其是透明细胞和子宫内膜样类型，其中 WT1 表达通常为阴性或仅局灶性。
The ovary is a common site of involvement for metastasis and the breast is one of the most common sources. Metastatic breast carcinoma can mimic a primary ovarian carcinoma. Pax8 is a crucial transcription factor for organogenesis of the thyroid gland, kidney, and Mullerian system, and it also regulates Wilms tumor suppressor gene (WT1) expression. A total of 124 cases of ovarian carcinomas (84 serous papillary, 18 endometrioid, 12 mucinous, 10 clear cell) and 243 cases of invasive breast carcinomas (178 ductal, 65 lobular) were immunostained with Pax8 and WT1 by tissue microarrays to see the differential expression. Pax8 reaction was found in 108 of 124 ovarian carcinomas (87.1 %) generally in diffuse staining, including 81 of 84 serous papillary carcinomas (96.4%). 16 of 18 endometrioid carcinomas (88.9%), 10 of 10 clear cell carcinomas (100%), and 1 of 12 mucinous carcinomas (8.3%), whereas WT1 expression was seen in 78 of 124 ovarian carcinomas (62.9'%), including 73 of 84 serous papillary carcinomas (86.9%), and 5 of 18 endometrioid carcinomas (27.8%), with no expression in all 10 clear cell carcinomas and 12 mucinous carcinomas. All the mammary carcinomas were completely negative for Pax8, but WT1 expression was seen in 5 of 243 cases (2.1%). Pax8 is a useful marker in the differential diagnosis of ovarian and breast carcinomas, and it seems to be superior to WTI for the diagnosis of all types of nonmucinous ovarian careinomas, notably clear cell and endometrioid types where WT1 expression is generally negative or only focal.